Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2009

View Archived Issues

GSK-2126458 shows potent preclinical antitumor activity; phase I trial under way

New camptothecin conjugate evaluated in phase I trial in advanced solid tumors

FIELD trial data support beneficial effects of fenofibrate in type 2 diabetes patients

Prasugrel more effective than clopidogrel in CAD patients with type 2 diabetes

Small-molecule compound BRA-101 reduces DSS-induced murine colitis

Novel AR antagonist ZR-291 exhibits potent preclinical activity in prostate cancer

Novartis' Onbrez Breezhaler approved in E.U. for patients with COPD

Daiichi Sankyo reports results from Q2 of 2009, ended September 30

Vertex reports results from third quarter of 2009

MicroDose Therapeutx acquires EPX-16006 from Epix

Johnson & Johnson submits NDA to FDA for tapentadol ER tablets for chronic pain

New recombinant Xyntha now available in Canada

Stryker agrees to acquire Ascent Healthcare Solutions

DiaMedica expands into neurological disorders through acquisition of Sanomune

Pacira reports results of phase III Exparel trial in postoperative pain

Roche reports encouraging results from phase III trials of taspoglutide in diabetes

Javelin submits NDA to FDA for Dyloject for acute moderate to severe pain in adults

Watson Pharmaceuticals acquires Arrow Group

Bayer Schering Pharma claims novel series of adenosine A1 agonists

Novel antibacterial agents disclosed by AstraZeneca

Merck & Co. describes beta3-adrenoceptor agonists for urinary incontinence

Agreement reached on U.S. approval pathway for Pompe disease treatment

Endo provides regulatory update on Aveed for men with low testosterone

FDA approves AstraZeneca's Seroquel for pediatric schizophrenia and bipolar mania

ExonHit Therapeutics launches AclarusDx Alzheimer's test

Epigallocatechin gallate possibly beneficial in open-angle glaucoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...